<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05065060</url>
  </required_header>
  <id_info>
    <org_study_id>PPMI-007</org_study_id>
    <nct_id>NCT05065060</nct_id>
  </id_info>
  <brief_title>Parkinson Progression Marker Initiative Online (PPMI Online)</brief_title>
  <official_title>Parkinson's Progression Markers Initiative Online Study (PPMI Online)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Michael J. Fox Foundation for Parkinson's Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parkinson Progression Marker Initiative Online (PPMI Online) is an observational study&#xD;
      collecting participant reported information from people with and without Parkinson's disease&#xD;
      (PD), for the goal of better understanding risk and predictive factors for PD.&#xD;
&#xD;
      PPMI Online is part of the broader Parkinson Progression Marker Initiative aimed at&#xD;
      identifying markers of disease progression for use in clinical trials of therapies to reduce&#xD;
      progression of PD disability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PPMI is a broad program that is expanding the goals of the original PPMI study, and will&#xD;
      include this PPMI Online protocol, as well the PPMI Clinical [NCT04477785], PPMI Remote, PPMI&#xD;
      Digital protocols (with external regulatory oversight). All participants in PPMI may be asked&#xD;
      to participate in one or all of these protocols and their enrollment in these studies may&#xD;
      occur in varying order. PPMI participants may also be asked to participate in additional PPMI&#xD;
      companion studies (as they are developed), which may only involve a subset of PPMI&#xD;
      participants based on their cohort designation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">December 2041</completion_date>
  <primary_completion_date type="Anticipated">December 2041</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale Ib &amp; II</measure>
    <time_frame>Baseline to 240 months</time_frame>
    <description>Evaluates self-reported motor and nonmotor Parkinson's disease symptoms</description>
  </primary_outcome>
  <enrollment type="Anticipated">500000</enrollment>
  <condition>Parkinson Disease</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>Observation</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        In PPMI Online, up to 500,000 participants with and without PD will be enrolled and&#xD;
        contribute data longitudinally and cross-sectionally using a web-based platform.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Parkinson Disease (PD) Participants:&#xD;
&#xD;
               -  Male or female age 18 years or older.&#xD;
&#xD;
               -  Has received a diagnosis of Parkinson's disease&#xD;
&#xD;
        Participants without PD:&#xD;
&#xD;
          -  Male or female age 18 years or older.&#xD;
&#xD;
          -  Has not received a diagnosis of Parkinson's disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline Tanner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth L Marek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Neurodegenerative Disorders</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>University of California, San Francisco</last_name>
    <phone>877-525-7764</phone>
    <email>info@ppmionline.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSF Movement Disorders and Neuromodulation Center (MDNC)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>UCSF</last_name>
      <phone>877-525-7764</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Caroline M Tanner</investigator_full_name>
    <investigator_title>Protocol Co- Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Parkinson</keyword>
  <keyword>Neurodegenerative Disorder</keyword>
  <keyword>Prodromal</keyword>
  <keyword>At Risk</keyword>
  <keyword>Participant Reported Outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

